PCSK9 and familial hypercholesterolemia: In this way, theoretically, PCSK9 inhibition should have an antithrombotic effect even though PCSK9 inhibitors, differently from statins, show no effect on fibrinogen and D-dimer levels in statin-intolerant patients with familial hypercholesterolemia [105].